Antibody-drug conjugates emerge as potent anti-tumor agents for gynecological cancers
Gynecological cancers, primarily cervical, ovarian, and uterine cancer, continue to be a significant threat to women’s health worldwide. While surgery and chemotherapy are the current standard treatment, patients often face…
Could reducing inflammation help combat fatigue in people with early-stage breast cancer?
New research reveals that inflammatory responses may play a role in different types of fatigue experienced by many people with cancer. The findings are published by Wiley online in CANCER,…
FDA approves PharmaMar’s Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination as First-line Maintenance Therapy for Extensive-stage Small Cell Lung Cancer
harmaMar (MSE:PHM) has announced that the U.S Food and Drug Administration (FDA) has granted approval for Zepzelca® (lurbinectedin) in combination with atezolizumab (Tecentriq®) as a maintenance treatment for adults with…
Genetic testing reduces risks from chemotherapy for gastrointestinal cancer patients
For some patients with gastrointestinal (GI) cancers like colorectal and pancreatic cancer, chemotherapy can cause severe, sometimes life-threatening side effects in those who carry certain genetic variants that can impact…
Long-term results from Testicular Cancer treatment are positive
A new study shows that by combining different chemotherapy drugs, testicular cancer remains highly treatable and often curable, even after first-line treatment fails. . The recent study published in the…
Esophageal cancer, is chemotherapy before and after surgery a new standard treatment? #ASCO24
For patients with locally advanced esophageal adenocarcinoma that can be treated with surgery, chemotherapy treatment before and after surgery improved survival when compared to chemoradiotherapy before surgery. The research will…